Ampio Pharmaceuticals receives audit opinion with going concern statement
PR News Wire
Englewood, Colorado, April 3, 2024
ENGLEWOOD, Colo. , April 3, 2024 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”) announced today that it previously announced in its Annual Report on Form 10 that As disclosed, we announced the following: The Company’s audited financial statements for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 27, 2024, include an unqualified audit opinion from the Company’s independent registered public accounting firm. This included an explanatory note about our company. ability to continue as a going concern; Further information can be found in Footnote 2 to our financial statements included in our Annual Report on Form 10-K. This announcement is made pursuant to Section 610(b) of the NYSE American LLC Company Guide, which requires public disclosure of receipt of an audit opinion that includes going concern provisions. This announcement does not represent a change or amendment to our financial statements or annual report on Form 10-K for the year ended December 31, 2023.
For more information, please contact us below.
Ampio Pharmaceuticals Co., Ltd.
Michael A. Martino
chief executive officer
mmartino@ampiopharma.com
SOURCE Ampio Pharmaceuticals, Inc.
